Optimizing Lead Therapeutic Compounds Against Infectious Diseases

优化针对传染病的先导治疗化合物

• 批准号: 9134294
• 负责人: GEORGE PAINTER
• 金额: $ 108.55万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-30 至 2016-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9134294
• 关键词: Clinical; Communicable Diseases; Development; Future; In Vitro; Lead; Pharmaceutical Chemistry; Series; Staging; Testing; Therapeutic; Toxic effect; chikungunya; drug candidate; in vivo; infectious disease treatment; novel; pre-clinical; small molecule; therapeutic development

To support the advancement of promising lead therapeutics to the clinical drug candidate stage for the treatment of infectious diseases. Activities that may be supported include medicinal chemistry and preclinical in vitro and in vivo testing of a lead compound series in order to produce profiles of their efficacy, synthetic feasibility, stability, and toxicity, which will be used to identify a novel small molecule drug candidate for future clinical development.

支持有前景的先导疗法进入临床候选药物阶段，用于治疗感染性疾病。 可能支持的活动包括药物化学和先导化合物系列的临床前体外和体内测试，以产生其功效，合成可行性，稳定性和毒性的概况，这将用于确定未来临床开发的新型小分子候选药物。